Literature DB >> 7889968

Treatment of cerebrospinal fluid shunt infections with teicoplanin.

M L Fernández Guerrero1, M de Górgolas, R Fernández Roblas, J M Campos.   

Abstract

Intraventricular teicoplanin 10-15 mg was administered daily to three patients with cerebrospinal fluid (CSF) shunt infections due to Staphylococcus epidermidis and Enterococcus faecalis. Teicoplanin concentrations in CSF 24 h after intrathecal injection of the drug exceeded four- to eight-fold the MICs for the infecting microorganisms. CSF cultures rapidly became negative and shunt devices were withdrawn and replaced in the same operative procedure. Intraventricular teicoplanin was well tolerated. No relapses occurred. Teicoplanin may be an alternative to vancomycin for the antimicrobial therapy of CSF shunt infections.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7889968     DOI: 10.1007/bf02111827

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  11 in total

1.  Poor penetration of teicoplanin into cerebrospinal fluid in patients with bacterial meningitis.

Authors:  J P Stahl; J Croize; M Wolff; J J Garaud; P Leclercq; F Vachon; M Micoud
Journal:  J Antimicrob Chemother       Date:  1987-07       Impact factor: 5.790

2.  Treatment of infections of cerebrospinal fluid shunts.

Authors:  R L McLaurin; P T Frame
Journal:  Rev Infect Dis       Date:  1987 May-Jun

3.  Intraventricular administration of teicoplanin in shunt associated ventriculitis caused by methicillin resistant Staphylococcus aureus.

Authors:  M Venditti; A Micozzi; P Serra; G Buniva; L Palma; P Martino
Journal:  J Antimicrob Chemother       Date:  1988-04       Impact factor: 5.790

4.  Infections of cerebrospinal fluid shunts: epidemiology, clinical manifestations, and therapy.

Authors:  S C Schoenbaum; P Gardner; J Shillito
Journal:  J Infect Dis       Date:  1975-05       Impact factor: 5.226

5.  Evaluation of intraventricular teicoplanin for the treatment of neurosurgical shunt infections.

Authors:  M Cruciani; A Navarra; G Di Perri; M Andreoni; M C Danzi; E Concia; D Bassetti
Journal:  Clin Infect Dis       Date:  1992-08       Impact factor: 9.079

6.  Treatment of CSF shunt infections with intrashunt plus oral antibiotic therapy.

Authors:  P T Frame; R L McLaurin
Journal:  J Neurosurg       Date:  1984-02       Impact factor: 5.115

7.  Teicoplanin in the therapy of staphylococcal neuroshunt infections.

Authors:  R Maserati; M Cruciani; M Azzini; C Carnevale; F Suter; E Concia
Journal:  Int J Clin Pharmacol Res       Date:  1987

8.  Teicoplanin in the treatment of infections by staphylococci, Clostridium difficile and other gram-positive bacteria.

Authors:  F de Lalla; D Santoro; E Rinaldi; F Suter; M Cruciani; M H Guaglianone; G Rizzardini; G Pellegata
Journal:  J Antimicrob Chemother       Date:  1989-01       Impact factor: 5.790

9.  Early termination of a prospective, randomized trial comparing teicoplanin and flucloxacillin for treating severe staphylococcal infections.

Authors:  P Calain; K H Krause; P Vaudaux; R Auckenthaler; D Lew; F Waldvogel; B Hirschel
Journal:  J Infect Dis       Date:  1987-02       Impact factor: 5.226

10.  Clinical evaluation of teicoplanin for therapy of severe infections caused by gram-positive bacteria.

Authors:  Y Glupczynski; H Lagast; P Van der Auwera; J P Thys; F Crokaert; E Yourassowsky; F Meunier-Carpentier; J Klastersky; J P Kains; E Serruys-Schoutens
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191

View more
  2 in total

Review 1.  Intrathecal Antibacterial and Antifungal Therapies.

Authors:  Roland Nau; Claudia Blei; Helmut Eiffert
Journal:  Clin Microbiol Rev       Date:  2020-04-29       Impact factor: 26.132

2.  Reinfection following initial cerebrospinal fluid shunt infection.

Authors:  Tamara D Simon; Matthew Hall; J Michael Dean; John R W Kestle; Jay Riva-Cambrin
Journal:  J Neurosurg Pediatr       Date:  2010-09       Impact factor: 2.375

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.